Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma

Honggang Liu; Tao Xin; Hongtao Duan; Yuanyong Wang; Changjian Shao; Yifang Zhu; Jiansheng Wang; Jianjun He

doi:doi:10.18632/aging.204814

← Back

Research Paper Volume 15, Issue 12 pp 5650—5661

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma

Figure 3. Prognostic analysis of the immune prognostic model (IPM). Kaplan-Meier curves of the difference in overall survival (OS) between high- and low-risk cases in (A–F) the whole The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts, (B) mucin 16 wild-type (MUC16^WT) subgroup, and (C) mucin 16 mutation (MUC16^MUT) subgroup. (D–G) Relationship between risk score (upper) and expression of two prognostic immune genes (bottom). (E–H) Time-dependent receiver operating characteristic (ROC) curve analysis of the IPM.